Day 1 :
Keynote Forum
Dr. Somil Singhal
Maharaja Agresen Medical University, India
Keynote: Histopathological spectrum of basal cell carcinoma- 7 years study
Time : 09:20-10:20
Biography:
Dr. Somil Singhal has completed his Bachelor Of Medicine and Surgery ( MBBS) at the age of 25 years of age from Beijing Medical University, China and Post Doctoral Studies in Doctor Of Medicine In Pathology from Ragiv Gandhi University Of Health Sciences, Bangalore, India. Currently he is working as Pathologist in the Haematology Departrment at Maharaja Agresen Group Of Hospitals , NewDelhi, India. He has attended various Conferences, CME’s and published Case studies , Dessertation in reputed journals like IJLSSR, Index Copernicus, Poland Journal Of Dermatology and is the life member of Indian Medical Association and Allahabad Medical Association. Besides this he had worked as a resident in AIIMS Trauma Center in the department of emergency medicine, Cardiac resident at Fortis Hospital Okhla, Delhi and attended various ITO and blood bank camps for service to hthe society.
Abstract:
Basal cell carcinoma is the most common form of skin cancer which is also known as Rodent Ulcer or Trichoblastic Carinomas. Howevver, it rarely metastatise and difficult to distinguish from various other skin adnexal tumors because of complexity and variety of skin tumors. The incidence world wide is > 100/100,000 being compared to India which is 25.9% / 100,000. Its a five years retrospective study from september 2004 to september 2007 i.e. 7 years. The results are maximum in the age group of 40-49 years of age and out of 21 cases maximum numbers are in between 60-69 years of age i.e. 8 cases. The foremost site prediliction was in eyelid followed by nose > forehead > cheek > ear > Scalp > and Post auricular region when compared with 12 cases of males and 9 cases of females. The most common histopathological pattern was found in Solid type of Bsal Cell Carcinoma comapred with Adenoid variant , Infiltrative variant , Basosquamous variant , Keratotic variant and pigmented varient. Presently, compared with cell morphology most nodular Basal Cell Cancer can be diagnosed clinically when compared with Intradermal Nevus, Sebacaemoas , Fibrous papules, Early acne scars and Hypertrophic scarrings. Therefore, the present study emphazises the various patterns of Basal Cell Carcinomas in the geographical location in and around the city.
- Drugs, Therapies and their Side Effects
Location: San Antonio, Texas
Chair
Dr. Daniel De Rossi Fattaccioli
Peru Dermatology Society, Peru
Session Introduction
Dr. Hima Bindu Gottam
TOLMAR Inc, USA
Title: Understanding Q hypotheses for developing topical generic drugs
Biography:
Bindu has completed her Bachelors in Pharmacy at the age of 21 years from Acharya Nagarjuna University, India and M.S. in Chemistry (Thesis) from Western Illinois University, US. She started her career as an Associate Scientist and worked on a variety of dosage forms including oral solutions, transdermal patches, topical dosage forms and parenteral dosage forms. She worked in generic dermatology industry over 8 years and has more than 18 ANDA approvals in US within short span and 8 more products are currently under filing with the agency. She has 2 publications in reputed journals and also completed her Regulatory Affairs Certification (RAC).
Abstract:
Topical drug delivery is considered one of the safest and easiest drug delivery approaches for many reasons. Topical formulations are designed to deliver drugs to the skin to treat skin disease conditions or to alleviate symptoms. Developing a dermatology generic drug product involves many regulations and needs critical understanding of the test product as well as reference product in order to make the test formulation structurally and functionally similar to the reference product. Current regulations require conducting clinical end point trials for demonstrating bioequivalence (BE) between topical generic and refernce listed drug (RLD) products. A variety of surrogate methods have been explored but with limited success. FDA has been continuously coming up with new regulatory standards to make high quality and affordable medicines available to public and the generic industry is trying to adapt to the new requirements. Bioequivalence sudies on topical products still remained one of the challenging topics in the generic industry because of two reasons: i) due to high complexity of topical dosage forms ii) due to lack of proper design of BE studies. The new GDUFA II guidance gives a clear pathway to assist generic pharmaceutical industry with identifying the most relevant methodologies for developing drugs and generating evidence needed to support ANDA approval. To develop a therapeutically equivalent drug product to a specific reference product, it is necessary to identify the key scientific principles for consistent and efficient identification of BE methods. Availability of product quality matrices i.e. Q1 (qualitatively the same), Q2 (quantitatively the same) and Q3 (microstructure/ physical attributes of the topical dosage form) is critical to demonstrate that generic topical product is therapeutically equivalent.
Dr. Prachi Chetankumar Gajjar
Government medical college, Bhavnagar, India
Title: “ Dermoscopy of congenital dermatoses in pediatric age group- An observational studyâ€
Biography:
Dr Prachi Chetankumar Gajjar is a third year resident doctor in Department of Dermatology. She has a keen interest in dermoscopy as well as pediatric dermatology. She has acquired training in research methology organized by Indian council of medical research held at Chennai. Following which she has contributed as an author in few publications in national and international journals. She has also delivered talk on “Clinical trial registry of India” in post graduate orientation programme held in Government medical college, Bhavnagar and on “Mucocutaneous manifestations of connective tissue disease” in Rhematology CME at the same venue. She has also presented E posters and oral presentation in state and national conferences in India.
Abstract:
Dr. Ruchi Shah
Baroda Medical College, India
Title: Thalidomide induced thrombocytopenia in a case of chronic cutaneous lupus erythematosus(CCLE)
Biography:
Abstract:
Introduction: Low-dose thalidomide is an effective treatment option for chronic cutaneous lupus erythematosus(CCLE) in resistant cases.Rarely, it can cause thrombocytopenia.
Clinical Summary: A 39 year old female presented to Dermatology OPD with CCLE.She had history of repeated episodes for 21years. On examination,unsightly lesions with scarring were present over face and scalp.She was given topical and oral Corticosteroids ,hydroxychloroquine etc.Thalidomide was then considered as disease was not responding to conventional therapy.
She was initially given Thalidomide 100mgBD for 2 weeks to which she responded well.It was later omitted by patient.One month later, she presented with exacerbation of LE and Thalidomide was restarted. However, after single dose of Thalidomide, she developed complaints of gradually progressing purpuric lesions over scalp and face.She also had complaint of menorrhagia. She was not on any other medications.On examination ,multiple purpuric lesions were present over preexisting CCLE plaques over forehead, malar area of face and scalp.Tablet Thalidomide was omitted.Investigation showed thrombocytopenia with platelet count of 4000/cumm and deranged coagulation profile with increased prothrombin time and decreased aPTT. The patient was hospitalized and administered 1 unit Packed Cell Volume of blood.She was followed up with daily haemogram.
An increasing trend in platelet count after cessation of Thalidomide, in absence of any other cause, was suggestive of Thalidomide induced thrombocytopenia,a rare,yet reported adverse effect.
Discussion: Thalidomide induced thrombocytopenia and neutropenia has been reported in cases of multiple myeloma.However,its occurrence in CCLE has not been observed.
Conclusion: Awareness about rare but fatal ADRs can save the life of patient.